ConceptioArchiveHAL (France)
HAL (France)open access

A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours

Christophe Le Tourneau et al.
HAL (France) · Papers · License: Open Access
Open Source ↗
0, 1
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 145066
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.